Research Article

PPARδ Agonist GW501516 Inhibits PDGF-Stimulated Pulmonary Arterial Smooth Muscle Cell Function Related to Pathological Vascular Remodeling

Guangjie Liu, 1 Xuan Li, 2,3 Yan Li, 2,3 Xin Tang, 2,3 Jie Xu, 1 Ran Li, 1 Peng Hao, 2,3 and Yongchang Sun 1

1 Department of Respiratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
2 Nankai University Eye Hospital, Tianjin 300020, China
3 Tianjin Eye Hospital, Tianjin Key Laboratory of Ophthalmology and Visual Science, Clinical College of Ophthalmology, Tianjin Medical University, Tianjin 300020, China

Correspondence should be addressed to Xuan Li; xuanli08@yahoo.com

Received 20 November 2012; Accepted 21 February 2013

Academic Editor: Gary S. Stein

Copyright © 2013 Guangjie Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pulmonary arterial hypertension (PAH) is a severe and progressive disease, a key feature of which is pulmonary vascular remodeling. Growth factors, cytokines, and lipid mediators are involved in this remodeling process. Recent reports suggest that the peroxisome proliferator-activated receptors (PPARs) play important roles in the regulation of cell growth and differentiation as well as tissue wounding and repair. In this study, we examined the role of PPARδ in the regulation of proliferation, migration, collagen synthesis, and chemokine production in human pulmonary arterial smooth muscle cells (HPASMCs). The data showed that PPARδ was the most abundant isoform in HPASMCs. PPARδ was upregulated in HPASMCs treated with PDGF, which is the major mediator in pulmonary vascular remodeling. Activation of PPARδ by GW501516, a specific PPARδ ligand, significantly inhibited PDGF-induced proliferation in HPASMCs. The inhibitory effect of GW501516 on HPASMCs was associated with decreased expression of cyclin D1, cyclin D3, CDK2, and CDK4 as well as increased expression of the cell cycle inhibitory genes G0S2 and P27kip1. Pretreatment of HPASMCs with GW501516 significantly inhibited PDGF-induced cell migration and collagen synthesis. GW501516 also significantly attenuated TNF-mediated expression of MCP-1. These results suggest that PPARδ may be a potential therapeutic target against the progression of vascular remodeling in PAH.

1. Introduction

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by increased pulmonary vascular resistance and pulmonary arterial pressure leading to right heart failure. The etiology and pathogenesis of PAH are complex and incompletely understood. Pulmonary vascular remodeling is a hallmark of most forms of PAH, including both primary and secondary PAHs. Accumulation of extracellular matrix including collagen as well as vascular smooth muscle cell proliferation and migration contribute to the muscularization of the pulmonary arterial wall, leading to a severe decrease of the cross-sectional area and therefore an increase in the right ventricular afterload [1, 2]. Growth factors and cytokines participate in the processes of abnormal vascular remodeling, inflammation, and cell proliferation involved in PAH [3]. PDGF is a potent mitogen involved in cell proliferation and migration. Active PDGF is composed of polypeptides (A and B chains) that form homo- or heterodimers that stimulate its cell surface receptors. Studies show that PDGF-B and the PDGFRβ are primarily required for the development of the vasculature. PDGF is synthesized by many different cell types including vascular smooth muscle cells (VSMCs), vascular endothelial cells (ECs), and macrophages. PDGF induces the proliferation and migration of VSMCs and has been proposed to be a key mediator in the progression of several fibroproliferative disorders, such as atherosclerosis, lung fibrosis, and PAH.
Inflammation has a key role during the development of PAH. Levels of cytokines and chemokines are elevated in the blood of patients with PAH (e.g., TNFα, soluble TNF-receptor type I, interleukin 1, and MCP-1) [6]. It is clear that PAH has a multifactorial pathobiology, and the current understanding of the mechanisms of PAH has facilitated the development of novel therapeutic strategies for PAH focused on the cell proliferation, vascular remodeling, and inflammation involved in PAH.

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors and members of the nuclear hormone receptor superfamily that includes three isoforms: PPARα, PPARγ, and PPARβ/δ. Ligand-activated PPARs form heterodimers with a retinoid X receptor (RXR) and bind to specific PPAR responsive elements (PPREs) to regulate target gene expression. The activation of PPARs modulates numerous biological processes including energy homeostasis, cell proliferation and differentiation, fatty acid catabolism, and adipogenesis. Although most studies have shown that PPARα and PPARγ exert anti-inflammatory, antiproliferative, and antiangiogenic properties in cardiovascular cells, the role of PPARδ in vascular pathophysiology is poorly understood [7, 8]. Intriguingly, recent literature suggests that the ligand activation of PPARδ induces the terminal differentiation of keratinocytes and inhibits cell proliferation [9, 10]. Prostacyclin (PGI2), the predominant prostanooid released by vascular cells, is a putative endogenous agonist for PPARδ, and the administration of PGI2 or its analogues represents a significant advance in PAH therapy [11, 12]. Overexpression of PGI2 synthase inhibits the growth of VSMCs and prevents neointimal formation in rat carotid arteries after balloon injury [13, 14]. In addition, inflammation plays a significant role in altering pulmonary vascular function during the development of PAH. The plexiform lesions that characterize severe PAH are surrounded by macrophages, T and B lymphocytes, and dendritic cells [15, 16]. Therefore, agents that target the generation of the inflammatory stimuli in the pulmonary vascular wall may reduce vascular dysfunction and attenuate the development or progression of PAH. Increasing evidence indicates the anti-inflammatory properties of PPARδ activation in some cell types and animal models. PPARδ activation inhibited the induction of MCP-1 and intercellular adhesion molecule-1 (ICAM-1) genes in a cardiac ischemia/reperfusion model [17]. Together, these observations raise the possibility that PPARδ mediates vascular remodeling by mitigating vascular smooth cell proliferation, extracellular matrix (ECM) production, and inflammation.

In the present study, we aimed to define the functional significance of PPARδ in pulmonary arterial smooth muscle cells. According to our data, PPARδ is abundantly expressed in HPASMCs, and we demonstrate that PDGF stimulation increases PPARδ expression by 2- to 3-fold in HPASMCs. Activation of PPARδ by GW501516 inhibits the PDGF-induced proliferation and migration of HPASMCs as well as collagen synthesis. Moreover, GW501516 exerts its inhibitory effects by regulating the PDGF-induced expression of cell cycle regulatory genes and attenuates the TNFα-induced MCP-1 expression in HPASMCs.

2. Materials and Methods

2.1. Materials. GW501516 was purchased from Calbiochem (San Diego, CA, USA). Platelet-derived growth factor (PDGF)-BB and tumor necrosis factor-α (TNF-α) were purchased from R&D (Minneapolis, MN, USA). Antibodies against PPARδ (sc-74440) or actin (sc-1616) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

2.2. Cell Culture. The human pulmonary arterial smooth muscle cells (HPASMCs) and human pulmonary arterial endothelial cells (HPAECs) were purchased from Lonza. HPASMCs and HPAECs were cultured according to the supplier’s instructions. Cells of passage 4-7 were subjected to serum starvation for 24 hours before being used for the experiments.

2.3. BrdU Incorporation Assay. Cellular proliferation was assayed with a kit from Roche that monitors the incorporation of BrdU into newly synthesized DNA. BrdU was detected using an anti-BrdU-peroxidase conjugate in accordance with the manufacturer’s instructions. The amount of BrdU incorporated was determined by measuring the absorbance at 450 nm.

2.4. Cell Migration: Transwell Assay. Migration assays were performed using a Boyden chamber. HPASMCs were digested with 0.05% trypsin and dispersed into homogeneous cell suspensions that were placed on the upper surface of an 8 μm pore size chamber. The upper chamber contained medium with GW501516 (3 μM), and cellular migration was induced by adding PDGF-BB (10 ng/mL) to the lower chamber. After 16 h, the nonmigrating cells were removed, and the membrane was fixed and stained. The results are expressed as the number of migrated cells per square millimeter.

2.5. Western Blot Analysis. Cell lysates were prepared with RIPA buffer containing the complete protease mix (Roche). Fifty micrograms of protein was subjected to SDS-PAGE and transferred to PVDF membranes. Protein expression was detected by chemiluminescence (Millipore) and quantified by densitometry.

2.6. 3H-Proline Incorporation Assay. Serum-starved HPASMCs were incubated with 1 μCi/mL 3H-proline (Amersham) along with PDGF after pretreatment with or without GW501516. After 24 h, the cells were washed with ice-cold PBS, treated with ice-cold 15% trichloroacetic acid (TCA) for 1 hour and then washed with ice-cold ethanol. The precipitants were solubilized in lysis buffer (2% SDS, 1 mM EDTA and 40 mM Tris, pH 7.4) for the liquid scintillation counting assay. The radioactive counts per minute (CPM) representing the amount of newly synthesized collagen were normalized to the total protein content.

2.7. Real-Time Reverse Transcription PCR. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA). The cDNA was generated using 2.5 μg of total RNA with the MultiScribe Reverse Transcriptase Kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR reactions were performed...
using a Bio-Rad iCycler with the SYBR Green Supermix (Bio-Rad), according to the manufacturer’s protocol. The primer sequences were as follows: GAPDH: forward, 5′-agggtcggctcttacactgtg-3′, reverse, 5′-caccctgctggaagaagctg-3′; PPARα: forward, 5′-ctcaacatgcaacagctgacg-3′, reverse, 5′-agccatcaacggtgcatgac-3′; PPARδ: forward, 5′-gggctgctgtgcgtctcgtg-3′, reverse, 5′-gggccctgtgagttg-3′; PPARγ: forward, 5′-ttctctttactctctcggcggc-3′; CyclinD1: forward, 5′-tctctccgtaatggaagacc-3′, reverse, 5′-atactcagagtctctccagtcacctgctgttat-3′; CyclinD3: forward, 5′-ctcagagtccgaaagat-3′, reverse, 5′-ctcacttgattttggaggga-3′; CDK2: forward, 5′-gcttcgatctgctcctgaca-3′, reverse, 5′-ggagccgggaatgaccttag-3′; CDK4: forward, 5′-atgttgtccggctgatgga-3′, reverse, 5′-caccagggttaccttgatctcc-3′; G0S2: forward, 5′-aaagatataagcggcccccg-3′, reverse, 5′-ctctctccgtaatggaagacc-3′; P27kip1: forward, 5′-tgcaacgctcagttcctttcacta-3′, reverse, 5′-caagcagtgatgtatctgataaacaagga-3′; MCP1: forward, 5′-ccccacttgattttggaggga-3′, reverse, 5′-agacgtcagtgatgtatctgataaacaagga-3′; CDK2: forward, 5′-gcttcgatctgctcctgaca-3′, reverse, 5′-ggagccgggaatgaccttag-3′; CDK4: forward, 5′-atgttgtccggctgatgga-3′, reverse, 5′-caccagggttaccttgatctcc-3′; G0S2: forward, 5′-aaagatataagcggcccccg-3′, reverse, 5′-ctctctccgtaatggaagacc-3′; P27kip1: forward, 5′-tgcaacgctcagttcctttcacta-3′, reverse, 5′-caagcagtgatgtatctgataaacaagga-3′; MCP1: forward, 5′-ccccacttgattttggaggga-3′, reverse, 5′-agacgtcagtgatgtatctgataaacaagga-3′. The results were stated as the fold difference expression for each gene compared to that of GAPDH, using the 2−ΔΔCt method.

2.8. Statistics. All measurements were expressed as mean ± SD. Student’s t-test was used for comparison between two groups, whereas an analysis of variance (ANOVA) was performed for multiple comparisons. All statistical analyses were performed using SPSS (v13.0). Statistical significance was defined as P < 0.05.

3. Results

3.1. PPAR Isoforms in HPASMCs and HPAECs. Using western blot analysis, we demonstrated that PPARδ protein was expressed in both cultured HPASMCs and HPAECs; moreover, expression of PPARδ was higher in HPASMCs than in HPAECs. Compared with PPARγ, a relatively high level of PPARδ protein was observed in both HPASMCs and HPAECs (Figure 1(a)). Real-time quantitative PCR confirmed the presence of the three PPAR isoforms in HPASMCs. The relative abundance for PPARα, PPARδ, and PPARγ mRNA was 1.00:4.90:2.19 (Figure 1(b)). These data document the differential expression patterns of the PPAR isoforms present in cultured HPASMCs.

3.2. PDGF Induced Expression of PPARδ in a Dose- and Time-Dependent Manner in HPASMCs. PPARδ has been linked to proliferation in some cell lines; furthermore, it was recently reported that PPARδ is upregulated during vascular lesion formation [18]. Whether PPARδ is associated with pulmonary vascular cells is unclear. Based on the investigation of abundant PPARδ in HPASMCs described above, we tested the expression of PPARδ in HPASMCs treated with PDGF, a key mediator in PAH pathogenesis and vascular remodeling. HPASMCs were treated with different doses of PDGF for 24 h. The dose response of PDGF-induced PPARδ production was determined. As shown in Figure 2(a), western blot analysis of the cell lysates indicated that PDGF upregulated PPARδ protein expression in a dose-dependent manner. A significant increase was observed at a PDGF concentration as low as 5 ng/mL, whereas the maximal increase was obtained at a concentration of 20 ng/mL. We tested the time course of the PDGF-induced PPARδ production in HPASMCs. HPASMCs were treated with 10 ng/mL PDGF for 0, 6, 12, 24, 48, or 72 h. As shown in Figure 2(c), western blot analysis revealed that PDGF upregulated PPARδ protein expression in the cell lysates as early as 6 h and reached a plateau at 24 h. These results demonstrate that PDGF induces PPARδ protein expression in a dose- and time-dependent manner in HPASMCs.

Next, we investigated the effects of PPARδ on cell biological processes of HPASMCs, including proliferation, migration, collagen synthesis, and chemokine production.
3.3. Ligand Activation of PPARδ Inhibited PDGF-Induced Proliferation of HPASMCs. We studied the effect of GW501516, a highly selective PPARδ agonist, on the proliferation of HPASMCs. In HPASMCs, BrdU incorporation was slightly reduced following GW501515 treatment. The HPASMCs were pretreated with GW501515 for 6 h followed by PDGF induction. BrdU incorporation was significantly reduced, by ∼28%, after GW501516 pretreatment (Figure 3(a)). Our data indicated that the ligand activation of the PPARδ decreased PDGF-induced proliferation of HPASMCs.

The effect of GW501516 was examined when serum was used to replace PDGF. Inhibition of cell proliferation was also observed in HPASMCs in response to GW501516 in culture medium containing FBS (data not shown).

To explore the potential mechanisms by which PPARδ influences the proliferation of HPASMCs, the mRNA levels of cell cycle regulatory genes, including cyclins and the cyclin-dependent kinases (CDKs), and cell cycle inhibitory genes were examined. As shown in Figure 3(b), PDGF induced significant increases in the mRNA levels of cyclin D1, cyclin D3, CDK2, and CDK4. Pretreatment with GW501516 significantly suppressed the PDGF-induced upregulation of those genes. The cell cycle inhibitor gene G0/G1 switch gene 2 (G0S2) has been proposed as a novel PPAR target gene [19]. The mRNA level of G0S2 in HPASMCs was significantly increased after GW501516 treatment. Moreover, pretreatment with GW501516 upregulated the expression of P27kip1 (P27), a CDK inhibitor that prevents cell proliferation by negatively regulating the activity of the cyclin-CDK complex.

3.4. Ligand Activation of PPARδ Inhibited PDGF-Induced Migration of HPASMCs. To determine the effect of GW501516 on the migration of HPASMCs, we performed an in vitro transwell assay. As shown in Figure 4(a), an
The chemokine MCP-1 has been proposed to play an important role in the initiation and/or progression of PAH. Immunoreactivity for MCP-1 was detected in the endothelium, the smooth muscle cells, and the macrophages within the neointima in hypertensive large elastic pulmonary arteries. Anti-MCP-1 gene therapy attenuated PAH in rats [20]. We examined the anti-inflammatory effect of GW501516 on MCP-1 expression in HPASMCs treated with the proinflammatory factor TNFα. GW501516 significantly inhibited the TNFα-induced increase in MCP-1 mRNA expression (Figure 4(c)).

4. Discussion

In the present study, the expression of PPARδ was found to be relatively high in HPASMCs compared with HPAECs. Moreover, three isoforms of PPARs were expressed in HPASMCs. In accordance with a previous finding that PPARδ is abundantly expressed in VSMCs [18, 21], we confirmed that PPARδ was the predominant isotype in HPASMCs. The vasculoproliferative disorders of PAH are characterized by the accumulation of vascular smooth muscle cells by proliferation and migration as well as extracellular matrix deposition. Cytokines and growth factors such as PDGF participate in these processes. We demonstrate that PPARδ is abundantly expressed in HPASMCs and that PDGF upregulates PPARδ expression in a time- and dose-dependent manner in HPASMCs; this finding is consistent with a previous report of PDGF inducing PGI2 expression in vascular cells [22]. These further suggest that PPARδ is involved in VSMCs proliferation during vascular lesion formation. This study provides evidence that the activation of PPARδ by a specific ligand, GW501516, attenuates the proliferation and migration of HPASMCs as well as the collagen synthesis that occurs in response to PDGF. This finding is consistent with a previous study reporting that PPARδ is upregulated in vascular smooth muscle cells during vascular lesion formation and that the upregulation of PPARδ may be a vascular compensatory response [18, 23].

VSMCs proliferation is a major component of the vasculoproliferative disorders. Vascular injury results in the release of growth factors and cytokines that stimulate quiescent VSMCs to enter the cell cycle. Cell cycle progression is dependent on the expression and activation of specific enzymes CKDs, which form complexes with their regulatory subunits, the cyclins. The cyclin-CDK complexes formed in cell cycle progression are regulated by CDK inhibitors, such as p21/Cip1 and p27/Kip1 [24]. This study revealed that GW501516, a selective ligand of PPARδ, diminished the proliferation of HPASMCs induced by PDGF. The expression of cell cycle regulatory genes in response to PPARδ activation in HPASMCs was investigated. GW501516 reduced the PDGF-induced expression of CKD2, CKD4, cyclin D1, and cyclin D3. In agreement with these changes, the mRNA expression of p27 was increased by GW501516. In addition, the expression of the cell cycle inhibitory gene G0S2 was upregulated after GW501516 treatment. Gene G0S2 contains a functional PPRE in the promoter region and has been confirmed as a novel PPAR target gene [19, 25]. These further suggested that the
ligand activation of PPARδ is involved in cell proliferation through the modulation of cell cycle regulatory genes. These findings are consistent with a recent report that a PGI2 analog mediated PPARδ activation and enhanced the transcriptional activation of the expression of p21/p27, which resulted in the antiproliferative effects in VSMCs [26]. However, considerable controversy remains concerning the role of PPARδ in cell growth, specifically whether PPARδ stimulates or inhibits cell proliferation. Some studies indicate that activating PPARδ causes increased cell proliferation in several different types of cells, including endothelial cells, keratinocytes, and cancer cells [27–29]. Additionally, PPARδ has been reported to play an antiapoptotic role resulting in cellular proliferation [30]. These discrepancies may be related to experimental variables, including the choice of cell and animal models, the particular background strain of PPARδ null mice, and the sites of PPARδ genetic knockouts. Further studies necessary to examine the specific mechanisms underlying the effects of the ligand activation of PPARδ in HPASMCs should include additional dose response analyses and quantitative measures of cell proliferation as well as comparative analyses of PPARδ-dependent changes in the expression of known PPARδ target genes.

The results of this study showed that ligand activation of PPARδ significantly attenuated the proliferation and migration of PHASMCs as well as the collagen synthesis that occurs in response to PDGF. The inhibitory effect of PPARδ on PDGF-stimulated PHASMCs functions was modest. Further studies are required to investigate the integrated effects of PPARδ on pulmonary vascular remodeling in vivo. The three PPARs have distinct but often complementary functions [31]. PPARs have been implicated in many normal and disease-related biological processes such as inflammation, tissue remodeling, and atherosclerosis. Studies show redundancy in the function of PPARα and PPARδ as transcriptional regulators of fatty acid homeostasis [31, 32]. It becomes clear that PPARs participate in the control of cell proliferation and differentiation. PPARα inhibits VSMCs proliferation by blocking G1/S cell cycle transition, through the induction of the CDK inhibitor p16INK4a [33]. PPARγ ligands decrease

![Figure 4](image-url)
PPARs are ligand-activated transcription factors. Once activated by a ligand, the receptors bind to the promoter elements of target genes. GW501516 is the first highly selective synthetic PPARδ agonist available. GW501516 binds to PPARδ with an IC50 of 1 nM and is at least 1000-fold more selective for PPARδ compared with PPARα and PPARγ [36]. Growing evidence has demonstrated that the ligand activation of PPARδ is involved in multiple biological processes involving lipid metabolism, glucose homeostasis, cell differentiation, and inflammation. We now report that PPARδ has a potent inhibitory effect on the PDGF stimulation of three major cell functions in HPASMCs, including proliferation, migration, and collagen synthesis. These data are consistent with the inhibitory effect of a PPARδ agonist on keratinocyte proliferation and the ability of cardiac fibroblasts to synthesize collagen in response to angiotensin II [37, 38]. Additionally, the ligand activation of PPARδ inhibited TNF-induced upregulation of MCP-1, which is consistent with its anti-inflammatory effects in vascular endothelial cells and in kidney [39, 40]. Taken together, our data demonstrate that the ligand activation of PPARδ reduced the proliferation of HPASMCs, an effect that was associated with the regulation of cell cycle regulatory gene expression. Furthermore, PPARδ activation reduced cell migration, collagen synthesis, and chemokine production. Because PPARδ is able to inhibit multiple aspects of vascular remodeling, it may be a therapeutic target for slowing the progression of vascular remodeling in PAH.

Acknowledgments

The authors thank Dr. Hideki Kimura and Dr. Takeshi Ishizaki (University of Fukui, Japan) for technical assistance and helpful discussions. This study was supported by Grants from the Scientific Research Foundation for Returned Scholars, the Ministry of Education of China (No. [2005]546), Tianjin Scientific & Technical Foundation (11JCYBJC27200), and the National Natural Science Foundation of China (81170828).

References

[1] M. Rabinovitch, "Molecular pathogenesis of pulmonary arterial hypertension," Journal of Clinical Investigation, vol. 118, no. 7, pp. 2372–2379, 2008.
[2] R. T. Schermuly, H. A. Ghofrani, M. R. Wilkins, and F. Griminger, "Mechanisms of disease: pulmonary arterial hypertension," Nature Reviews Cardiology, vol. 8, no. 8, pp. 443–455, 2011.
[3] L. Farkas, J. Gauldie, N. F. Voelkel, and M. Kolb, "Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors," The American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 1, pp. 1–15, 2011.
[4] A. Siegbahn, M. Johnell, A. Nordin, M. Åberg, and T. Velling, "TE/FVIIa transactivates PDGFβR to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 1, pp. 135–141, 2008.
[5] F. Perros, D. Montaní, P. Dorfmüller et al., "Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension," The American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 1, pp. 81–88, 2008.
[6] P. Crosswhite and Z. Sun, "Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension," Journal of Hypertension, vol. 28, no. 2, pp. 201–212, 2010.
[7] P. Sertznig, M. Seifert, W. Tilgen, and J. Reichrath, "Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer," Journal of Cellular Physiology, vol. 212, no. 1, pp. 1–12, 2007.
[8] A. Chawla, "Control of macrophage activation and function by PPARs," Circulation Research, vol. 106, no. 10, pp. 1559–1569, 2010.
[9] J. Lee and W. Y. Chung, "The role played by the peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) activator, GW501516, in control of fatty acid metabolism: a new potential therapeutic target for treating metabolic syndrome," Endocrinology, vol. 152, no. 5, pp. 1742–1744, 2011.
[10] H. C. Chong, M. J. Tan, V. Philippe et al., "Regulation of epithelial-mesenchymal IL-1 signaling by PPARβ/δ is essential for skin homeostasis and wound healing," Journal of Cell Biology, vol. 184, no. 6, pp. 817–831, 2009.
[11] F. Y. Ali, K. Egan, G. A. FitzGerald et al., "Role of prostacyclin versus peroxisome proliferator-activated receptor β receptors in prostacyclin sensing by lung fibroblasts," The American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 2, pp. 242–246, 2006.
[12] Y. Li, M. Connolly, C. Nagaraj et al., "Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation," The American Journal of Respiratory and Critical Care Medicine, vol. 46, no. 3, pp. 372–379, 2012.
[13] J. Yang, X. Li, R. Al-Lamkiet al., "Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo," Circulation Research, vol. 107, no. 2, pp. 252–262, 2010.
[14] M. C. Tsai, L. Chen, J. Zhou et al., "Shear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor α/δ activations by prostacyclin released by sheared endothelial cells," Circulation Research, vol. 105, no. 5, pp. 471–480, 2009.
[15] E. Stacher, B. B. Graham, J. M. Hunt et al., "Modern age pathology of pulmonary arterial hypertension," The American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 3, pp. 261–272, 2012.
[16] R. M. Tuder, B. Groves, D. B. Badesch, and N. F. Voelkel, "Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension," The American Journal of Pathology, vol. 144, no. 2, pp. 275–285, 1994.
from ischemia/reperfusion injury in Zucker fatty rats,"*Journal of Pharmacology and Experimental Therapeutics*, vol. 325, no. 2, pp. 466–474, 2008.

[18] J. Zhang, M. Fu, X. Zhu et al., "Peroxisome proliferator-activated receptor δ is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells,"*Journal of Biological Chemistry*, vol. 277, no. 13, pp. 11505–11512, 2002.

[19] F. Zandbergen, S. Mandard, P. Escher et al., "The G0/G1 switch gene 2 is a novel PPAR target gene,"*Biochemical Journal*, vol. 392, no. 2, pp. 313–324, 2005.

[20] Y. Ikeda, Y. Yonemitsu, C. Kataoka et al., "Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats," *The American Journal of Physiology*, vol. 283, no. 5, pp. H2021–H2028, 2002.

[21] E. E. Girroir, H. E. Hollingshead, P. He, B. Zhu, G. H. Perdew, and J. M. Peters, "Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice,"*Biochemical and Biophysical Research Communications*, vol. 371, no. 3, pp. 456–461, 2008.

[22] S. R. Coughlin, M. A. Moskowitz, and B. R. Zetter, "Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor,"*Nature*, vol. 288, no. 5791, pp. 600–602, 1980.

[23] M. Hamblin, L. Chang, Y. Fan, J. Zhang, and Y. E. Chen, "PPARs and the cardiovascular system," *Antioxidants and Redox Signaling*, vol. II, no. 6, pp. 1415–1452, 2009.

[24] H. A. Collier, "What's taking so long? S-phase entry from quiescence versus proliferation,"*Nature Reviews Molecular Cell Biology*, vol. 8, no. 8, pp. 667–670, 2007.

[25] B. E. J. Teunissen, P. J. H. Smeets, P. H. M. Willemsen, L. J. de Windt, G. J. van der Vusse, and M. van Bilsen, "Activation of PPARδ inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts,"*Cardiovascular Research*, vol. 75, no. 3, pp. 519–529, 2007.

[26] Y. M. Sue, C. P. Chung, H. Lin et al., "PPARδ-mediated p21/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells," *The American Journal of Physiology*, vol. 297, no. 2, pp. C321–C329, 2009.

[27] M. Romanowska, N. Al Yacoub, H. Seidel et al., "PPARγ enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor," *Journal of Investigative Dermatology*, vol. 128, no. 1, pp. 110–124, 2008.

[28] L. Piqueras, A. R. Reynolds, K. M. Hodivala-Dilke et al., "Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 27, no. 1, pp. 63–69, 2007.

[29] D. Wang, H. Wang, Y. Guo et al., "Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 50, pp. 19069–19074, 2006.

[30] M. Schuster, C. C. Zouboulis, F. Ochsendorf et al., "Peroxisome proliferator-activated receptor activators protect sebocytes from apoptosis: a new treatment modality for acne?" *British Journal of Dermatology*, vol. 164, no. 1, pp. 182–186, 2011.

[31] L. Michalik, B. Desvergne, C. Dreyer, M. Gavillet, R. N. Laurini, and W. Wahli, "PPAR expression and function during vertebrate development," *International Journal of Developmental Biology*, vol. 46, no. 1, pp. 105–114, 2002.

[32] D. M. Muoio, P. S. MacLean, D. B. Lang et al., "Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPARα) knock-out mice. Evidence for compensatory regulation by PPARδ," *Journal of Biological Chemistry*, vol. 277, no. 29, pp. 26089–26097, 2002.

[33] F. Gizard, C. Amant, O. Barbier et al., "PPARδ inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a," *Journal of Clinical Investigation*, vol. 115, no. 11, pp. 3228–3238, 2005.

[34] S. Wakino, U. Kintscher, S. Kim, F. Yin, W. A. Hsueh, and R. E. Law, "Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and GI → S transition in vascular smooth muscle cells," *Journal of Biological Chemistry*, vol. 275, no. 29, pp. 22435–22441, 2000.

[35] M. Fu, X. Zhu, Q. Wang et al., "Platelet-derived growth factor promotes the expression of peroxisome proliferator-activated receptor γ in vascular smooth muscle cells by a phosphatidylinositol 3-kinase/Akt signaling pathway," *Circulation Research*, vol. 89, no. 11, pp. 1058–1064, 2001.

[36] M. L. Sznaidman, C. D. Haffner, P. R. Maloney et al., "Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ): synthesis and biological activity," *Bioorganic and Medicinal Chemistry Letters*, vol. 13, no. 9, pp. 1517–1521, 2003.

[37] H. Zhang, R. Pi, R. Li et al., "PPARβ/δ activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts," *Archives of Biochemistry and Biophysics*, vol. 460, no. 1, pp. 25–32, 2007.

[38] M. G. Borland, J. E. Foreman, E. E. Girroir et al., "Ligand activation of peroxisome proliferator-activated receptor-β/δ inhibits cell proliferation in human HaCaT keratinocytes," *Molecular Pharmacology*, vol. 74, no. 5, pp. 1429–1442, 2008.

[39] Y. J. Liang, Y. C. Liu, C. Y. Chen et al., "Comparison of PPARδ and PPARγ in inhibiting the pro-inflammatory effects of C-reactive protein in endothelial cells," *International Journal of Cardioiology*, vol. 143, no. 3, pp. 361–367, 2010.

[40] X. Yang, S. Kume, Y. Tanaka et al., "GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFkappaB pathway in mice," *PloS One*, vol. 6, no. 9, Article ID e25271, 2011.